Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14327689 | 0.85 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12730537 | 0.84 | CYP4F2 (0.47) | PPARDHPGDSGAATSHRSYK | |
| SCHEMBL1657111 | 0.83 | CYP1A2 (0.48) | CDK2HPGDSHTTKDM4E | |
| SCHEMBL1301002 | 0.81 | PRKCI (0.50) | — | |
| SCHEMBL31500156 | 0.79 | CYP4F2 (0.46) | HPGDSTSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL3670334 | 0.78 | CASP3 (0.48) | PPARDGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13181038 | 0.78 | NPC1 (0.40) | HPGDSTSHRHTTGABRG2GABRB3 | |
| SCHEMBL1579740 | 0.78 | ADRB2 (0.46) | ENPP2 | |
| SCHEMBL29550622 | 0.78 | SMN1; SMN2 (0.40) | HPGDSLMNATSHRHTTGABRG2 | |
| SCHEMBL1295919 | 0.78 | SMN1; SMN2 (0.40) | HPGDSLMNATSHRHTTGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563561-B2 | 3-(3-pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2013-10-22 | — | — | US | disclosed |
| US-8563561-B2 | 3-(3-pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2013-10-22 | — | — | US | disclosed |
| US-8563561-B2 | 3-(3-pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2013-10-22 | — | — | US | disclosed |
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| EP-2367827-B1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4]TRIAZOLO [4,3-b]PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257172-A1 | 3-(3-Pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-10-20 | — | — | US | disclosed |
| US-20110257172-A1 | 3-(3-Pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-10-20 | — | — | US | disclosed |
| EP-2367827-A1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-Ý1,2,4¨TRIAZOLO Ý4,3-B¨PYRIDAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2358715-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2010072301-A1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072301-A1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010069441-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009152920-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257172-A1 | 3-(3-Pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives | RET, JAK2, TYRO3 | PPARD 1951/4885GRIN2D 2099/4885GRIN3B 1801/4885 |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | RET, ERBB2, JAK2 | PPARD 2180/4885GRIN2D 1635/4885GRIN3B 1577/4885 |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | RET, ERBB2, MET | PPARD 2091/4885GRIN2D 1760/4885GRIN3B 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.